key: cord-0912995-xc5gdd2f authors: Woodhouse, Ashley G.; Orvin, Chelsea; Rich, Caleb; Crosby, Joseph; Keedy, Chelsea A. title: Diabetes outcomes before and during tele-health advancements surrounding COVID-19 date: 2021-09-29 journal: J Am Pharm Assoc (2003) DOI: 10.1016/j.japh.2021.09.011 sha: 84f8147a38d43a3c6ea78f56ffb16dd62b1ab9ee doc_id: 912995 cord_uid: xc5gdd2f Background Pharmacists can optimize outcomes related to diabetes mellitus (T2DM) by taking advantage of telehealth opportunities despite the COVID-19 Public Health Emergency (COVID-19 PHE). Objective Identify and compare changes in T2DM outcomes prior to (August 2019 through February 2020) and during (March 2020 through October 2020) the COVID-19 PHE. Secondary objectives were to identify and compare pay-for-performance metrics and additional fee-for-service submitted in these patients. Methods This study examined changes in T2DM outcomes at one primary care office within a community health system. Pharmacists started regularly using Remote Patient Monitoring (RPM) services during the COVID-19 PHE to reduce in-person visits. Patients with an initial A1C greater than or equal to 8% were included. Data collected included comorbidities, change in A1C, and diabetes and statin medication therapy adherence. Percentage of Healthcare Effectiveness Data and Information Set (HEDIS) and Merit-Based Incentive Payment System (MIPS) measures met, and billing code frequencies were also assessed. Results In the pre COVID-19 PHE group (N=30), the average three and six month A1C reductions were 1.3% and 1.2%, respectively, while the reductions were 2.0% and 2.2% in the during COVID-19 PHE group (N=61). The percentage of patients appropriately initiated or maintained on statins was 96.2% in the pre COVID-19 PHE group versus 82.6% in the during COVID-19 PHE group. Related to HEDIS, statin adherence was 95.2% in the pre COVID-19 PHE group and 84.2% in the during COVID-19 PHE group while A1C control was 41.7% versus 54%, respectively. A1C control related to MIPS was 60% pre COVID-19 PHE versus 73.8% during the COVID-19 PHE. Diabetes medication adherence related to HEDIS and medication reconciliation related to MIPS was 100% for both groups. Conclusion Data demonstrates the opportunity for pharmacists to maintain and improve clinical outcomes related to T2DM despite the ongoing COVID-19 PHE through implementation of telephonic monitoring. Background: Pharmacists can optimize outcomes related to diabetes mellitus (T2DM) by taking 3 advantage of telehealth opportunities despite the COVID-19 Public Health Emergency (COVID-4 19 PHE). 5 6 Objective: Identify and compare changes in T2DM outcomes prior to (August 2019 through 7 February 2020) and during (March 2020 through October 2020) the COVID-19 PHE. Secondary 8 objectives were to identify and compare pay-for-performance metrics and additional fee-for-9 service submitted in these patients. 10 11 Methods: This study examined changes in T2DM outcomes at one primary care office within a 12 community health system. Pharmacists started regularly opportunity for pharmacists to maintain and improve clinical 30 outcomes related to T2DM despite the ongoing COVID-19 PHE through implementation of 31 telephonic monitoring. 32 33 34 35 36 37 38 39 40 41 42 43 44 Key Points 45 -What was already known 46 o Pharmacists are an important component of the multi-disciplinary teams needed to 47 improve outcomes in patients with T2DM 48 o Remote patient monitoring is an alternative method for disease state management in the 49 ambulatory care setting 50 -What this study adds 51 o Example of improved patient outcomes under indirectly supervised pharmacist telehealth 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 Despite its availability prior to the COVID-19 PHE, RPM services were not utilized until the 232 COVID-19 PHE presented the need to reduce in-person visits while sustaining both clinical and 233 fiscal outcomes related to pharmacist provided care. Implementation of these services also 234 allowed pharmacists in this setting to maintain the same quality of direct patient care 235 experiences for pharmacy students and residents during a time of reduced in-person visits. 236 While there were more total in-person visits during the COVID-19 PHE, this group included 237 twice as many patients therefore increasing the total number of patients reached and expanding 238 patient access. RPM allowed for this reduction of in-person visits while maintaining the same 239 standard of patient care. A potential explanation for higher visit numbers during the COVID-19 240 PHE is that RPM services allowed more frequent contact with patients as it was often more 241 convenient for them, therefore increasing engagement and rapport. Increased outcomes may be 242 a result of this increased patient interaction. 243 244 During the study period, RPM was able to be utilized via telephonic systems, including audio 245 only, that incorporated patient reported physiologic data (i.e. self-reported blood glucose or 246 blood pressure Available at: 278 www.cdc.gov/diabetes/data/statistics-report/diagnosed-undiagnosed-diabetes Glycemic targets: standards of medical care in diabetes-281 2021. Dia Care Cardiovascular disease and risk management: standards of 283 medical care in diabetes-2021. Dia Care Classification and diagnosis of diabetes: standards of 285 medical care in diabetes-2021. Dia Care Pharmacist interventions in the management of 287 type 2 diabetes mellitus: a systematic review of randomized controlled trials Medicare Telemedicine Health Care Provider Fact Sheet. Telehealth-CMS.gov 296 8. Final policy, payment, and quality provisions changes to the medicare physician fee schedule 297 for calendar year 2021